Filovirus Vaccines

Overview

Journal Hum Vaccin

Specialty Allergy & Immunology

Date 2011 Apr 27

PMID 21519188

Citations 20

Authors

Steven B Bradfute

John M Dye Jr

Sina Bavari

Affiliations

Soon will be listed here.

Abstract

Filoviruses can cause severe and often fatal hemorrhagic fever in humans and non-human primates (NHPs). Although there are currently no clinically proven treatments for filovirus disease, much progress has been made in recent years in the discovery of therapeutics and vaccines against these viruses. A variety of vaccine platforms have been shown to be effective against filovirus infection. This review summarizes the literature in this field, focusing on vaccines that have been shown to protect NHPs from infection. Furthermore, the uses of rodent models in vaccine development, as well as correlates of immunity, are discussed.

Citing Articles

Filoviruses: Innate Immunity, Inflammatory Cell Death, and Cytokines.

Lu J, Gullett J, Kanneganti T Pathogens. 2022; 11(12).

PMID: 36558734 PMC: 9785368. DOI: 10.3390/pathogens11121400.

Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?.

Meyer M, Malherbe D, Bukreyev A Trends Microbiol. 2018; 27(1):8-16.

PMID: 30201511 PMC: 6309495. DOI: 10.1016/j.tim.2018.08.008.

Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.

Froude J, Herbert A, Pelat T, Miethe S, Zak S, Brannan J Viruses. 2018; 10(6).

PMID: 29861435 PMC: 6024315. DOI: 10.3390/v10060286.

Generation and characterization of protective antibodies to Marburg virus.

Froude J, Pelat T, Miethe S, Zak S, Wec A, Chandran K MAbs. 2017; 9(4):696-703.

PMID: 28287337 PMC: 5419075. DOI: 10.1080/19420862.2017.1299848.

Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.

Konduru K, Shurtleff A, Bradfute S, Nakamura S, Bavari S, Kaplan G PLoS One. 2016; 11(9):e0162446.

PMID: 27622456 PMC: 5021345. DOI: 10.1371/journal.pone.0162446.

References

Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A . Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 1998; 239(1):206-16. DOI: 10.1006/viro.1997.8883. View

Yu J, Liao H, Gerdon A, Huffman B, Scearce R, McAdams M . Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. J Virol Methods. 2006; 137(2):219-28. DOI: 10.1016/j.jviromet.2006.06.014. View

Croyle M, Patel A, Tran K, Gray M, Zhang Y, Strong J . Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 2008; 3(10):e3548. PMC: 2569416. DOI: 10.1371/journal.pone.0003548. View

Warfield K, Posten N, Swenson D, Olinger G, Esposito D, Gillette W . Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis. 2007; 196 Suppl 2:S421-9. DOI: 10.1086/520612. View

Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D . Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004; 11(2):351-7. PMC: 371218. DOI: 10.1128/cdli.11.2.351-357.2004. View

Kobinger G, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F . Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2005; 346(2):394-401. DOI: 10.1016/j.virol.2005.10.042. View

Hofmann H, Kunz C . [A strain of "Marburg virus" (Rhabdovirus simiae) pathogenic to mice]. Arch Gesamte Virusforsch. 1970; 32(2):244-8. DOI: 10.1007/BF01249960. View

Qiu X, Fernando L, Alimonti J, Melito P, Feldmann F, Dick D . Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009; 4(5):e5547. PMC: 2678264. DOI: 10.1371/journal.pone.0005547. View

Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K . Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet. 1995; 346(8991-8992):1669-71. DOI: 10.1016/s0140-6736(95)92841-3. View

10.

Swenson D, Warfield K, Larsen T, Alves D, Coberley S, Bavari S . Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines. 2008; 7(4):417-29. DOI: 10.1586/14760584.7.4.417. View

11.

Fuller C, Ruthel G, Warfield K, Swenson D, Bosio C, Aman M . NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell Microbiol. 2007; 9(4):962-76. DOI: 10.1111/j.1462-5822.2006.00844.x. View

12.

Johnson E, Jaax N, White J, Jahrling P . Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol. 1995; 76(4):227-36. PMC: 1997182. View

13.

Richardson J, Yao M, Tran K, Croyle M, Strong J, Feldmann H . Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One. 2009; 4(4):e5308. PMC: 2669164. DOI: 10.1371/journal.pone.0005308. View

14.

Kuhn J . Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Arch Virol Suppl. 2008; 20:13-360. View

15.

Ryabchikova E, Kolesnikova L, Luchko S . An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis. 1999; 179 Suppl 1:S199-202. DOI: 10.1086/514293. View

16.

Geisbert T, Daddario-DiCaprio K, Geisbert J, Reed D, Feldmann F, Grolla A . Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008; 26(52):6894-900. PMC: 3398796. DOI: 10.1016/j.vaccine.2008.09.082. View

17.

Bray M . The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol. 2001; 82(Pt 6):1365-1373. DOI: 10.1099/0022-1317-82-6-1365. View

18.

Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A . Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998; 251(1):28-37. DOI: 10.1006/viro.1998.9367. View

19.

Pratt W, Wang D, Nichols D, Luo M, Woraratanadharm J, Dye J . Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol. 2010; 17(4):572-81. PMC: 2849326. DOI: 10.1128/CVI.00467-09. View

20.

Bukreyev A, Yang L, Zaki S, Shieh W, Rollin P, Murphy B . A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol. 2006; 80(5):2267-79. PMC: 1395378. DOI: 10.1128/JVI.80.5.2267-2279.2006. View